TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Interest of Using an Electric Wheelchair Equipped With Anti-collision Sensors for Elderly People in EHPAD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Over 60 years of age,~* Resident in an institution for the elderly or nursing home,~* with a electric wheelchair but expressing driving difficulties~* Having freely consented to participate in the study,~* In the case of a guardianship, the legal representative having read the information document intended for the legal guardian of an adult under legal protection (under guardianship) and having given his or her free and informed consent for the person for whom he or she is responsible to participate in the study (in agreement with the patient).~Exclusion Criteria:~* Impaired comprehension preventing the protocol from being carried out,~* Person in an emergency situation unable to give prior consent

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Use of an electric wheelchair with or without sensors (Type: OTHER): During 3 weeks, the electric weehlchair will not have sensors, then sensors will be put on the wheelchair for the next 3 weeks then removed for 3 other weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological diagnosis of non-small cell lung cancer that is Stage III (T1-3, pN2, M0) NSCLC in whom neoadjuvant therapy is recommended.~* Must have had a mediastinoscopy to determine nodal status and potential resectability~* Must have enough tissue from the biopsy for tissue marker determination for correlative studies~* Negative metastatic work up (FDG PET/CT, brain CT or MRI)~* No prior thoracic radiotherapy will be permitted~* Age 18 years or greater~* ECOG performance status 0-1 (Karnofsky at least 70%)~* Normal organ and marrow function~* No known HIV infection~* Not pregnant~* Ability to understand and the willingness to sign an informed consent document~Exclusion Criteria:~* Patients requiring a pneumonectomy~* Patients who have had chemotherapy or radiation therapy within 4 weeks prior to entering the study, or who have not recovered from adverse events due to agents administered earlier.~* Prior thoracic radiation~* Treatment with any other investigational agents.~* Known metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to NFV~* Patients receiving drugs contraindicated with NFV will be excluded.~* Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study compliance.~* Pregnant or lactating women~* HIV-positive patients on combination antiretroviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nelfinavir (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: QuiremSpheres Observational Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient with diagnosis of primary liver tumor or metastases in the liver from other primary cancers, allocated to SIRT with QuiremSpheres® as decided by a multidisciplinary tumor board~* Patient is ≥ 18 years~* Patient has understood and signed written informed consent to data collection in the study~Exclusion Criteria:~* Patient's refusal~* Local practice guidelines prohibiting the patient to receive SIRT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent.~* Male or female aged ≥ 18 years old.~* Diagnosis of moderate to severe dry eye syndrome~Exclusion Criteria:~* Pregnancy, lactation.~* Childbearing potential woman who is not using a reliable method of contraception and is not surgically sterilised.~* Inability of patient to understand the study procedures and thus inability to give informed consent.~* Non-compliant patient~* Participation in another clinical study at the same time as the present study.~* Participation to the present study during the exclusion period of another clinical study.~* Already included once in this study.~* Ward of court.~* Patient not covered by government health care scheme

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T2762 (Type: EXPERIMENTAL): One drop of T2762 in each eye 3 to 6 times daily
- Optive (Type: ACTIVE_COMPARATOR): One drop of Optive in each eye 3 to 6 times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Closure of Fasciotomy Wounds: A Prospective, Observational Study of a Continuous External Tissue Expander

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years of age or older~* Patients undergoing fasciotomy for decompression of compartment syndrome, evolving compartment syndrome, or prophylactically to prevent compartment syndrome~Exclusion Criteria:~* Patient younger than 18 years of age~* Patients with an active infection~* Patients unable to comply with protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vessel Loop fasciotomy closure (Type: ACTIVE_COMPARATOR): Fasciotomy closure using vessel loops and staples.
- DermaClose fasciotomy closure (Type: EXPERIMENTAL): Fasciotomy closure via DermaClose device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Individuals may be eligible for this study if they are 18 years of age or older and:~* Have one of the following types of T-Cell Lymphoproliferative disorders such as Cutaneous T-cell Lymphoma (CTCL), Peripheral T-cell Lymphoma (PCTL), Large Cell Lymphoma (LGL), or Adult T-cell Lymphoma (ATL). Patients should have disease that is resistant or refractory to the front-line therapy, except ATL patients for whom there is no standard therapy.~* At least 30% of tumor cells must be CD2 positive.~* Karnofsky Performance status of greater than or equal to 70% (able to care for themselves; but unable to carry on normal activity or to do active work).~* At least 3 weeks must have passed since prior systemic cytotoxic chemotherapy, prolonged or cytolytic steroid therapy or major surgery, and all treatment-related toxicities must have resolved prior to the first MEDI-507 administration (except thrombocytopenia).~* Have no prior treatment with MEDI-507.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study of Psychomotor Development and Attachment in Children Aged 6 to 30 Months With Oral Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age: 6 to 30 months~* Oral disorder defined by a MCH score ≥ 61~Exclusion Criteria:~* Children in enteral nutrition asked for an indication other than oral disorders~* Children followed for serious chronic organic pathology causing disorders of the oral (DNTC, swallowing disorders, etc.)~* Child already assessed by the psychomotrician who participated in the study~* Placement of the child in a medical institution or in a foster family.~* Parents' refusal to participate in the study~* Establishment of a psychomotor follow-up between the time of the medical consultation and the psychomotor evaluation.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 30 Months
- Healthy Volunteers: f

Study Arms:
- Psychomotor/psychological evaluation (Type: None): Children in the study aged 6 to 30 months followed or referred to CHIC for oral disorders will have a psychomotor assessment and a psychological interview. Questionnaires on eating behavior will also be proposed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CHG Dressings in Children With Central Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients 2 months to 18 years of age admitted with a central venous catheter expected to be in place for \> 48 hours.~Exclusion Criteria:~* Patients with known allergies to chlorhexidine or Tegaderm and those previously enrolled in this study will be excluded.~* Patients with portacatheters

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Tegaderm CHG clear dressing (Type: EXPERIMENTAL): Patients randomized to receive Tegaderm CHG clear dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
- Standard clear Tegaderm dressing (Type: ACTIVE_COMPARATOR): Patients randomized to receive standard clear Tegaderm dressing. All central line care will remain uniform between the two groups as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are able to read, comprehend, and sign the consent form, and willing to stay in the study unit for up to 12 hours.~* Patients who are reliable, cooperative, and of adequate intelligence to record the requested information on the questionnaire form(s).~* Women of childbearing potential who are not pregnant, as assessed by a urine pregnancy quick test on the day of the procedure, prior to surgery. Women must be using a method of birth control deemed acceptable by the investigator and continue to use this method during the duration of dosing with study medication~* Patient who develop sufficient levels of pain (rated at 50mm or more out of a 100 mm) on the DPIS within 6 hours post-surgical extraction.~* Patients who agree not to take analgesics other than protocol-defined rescue analgesics during the post-operative treatment period of 6 hours.~  * Patients who agree to refrain from alcohol and sedative consumption during the post-operative period of 6 hours.~* Patients scheduled to undergo surgical removal of 3 or more impacted third molars, at least 1 of which must be a bony mandibular impaction. In addition, the sum of the dental impaction scores must be 9 or above, carried out by investigator.~Exclusion Criteria:~Subjects with:~* Known opioids and NSAIDs allergies (or induced asthmatic attacks)~* Known history of opioid abuse~* Recent history of gastrointestinal ulceration~* History of aspirin intolerance/cross-sensitivity~* Recent myocardial disease~* Uncontrolled hypertension~* Patients receiving anticoagulation therapy~* Uncontrolled diabetes~* Pregnant women~* Immunosuppression~* Recent history of opioid or NSAID therapies~* Subjects who do not achieve a qualifying baseline pain threshold of 50mm out of 100mm on the visual analog DIPS within 6 hours of completion of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Standard of Care (Type: ACTIVE_COMPARATOR): Individuals within this group will receive standard of care for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)
- Pharmacogenomic Group (Type: EXPERIMENTAL): Individuals within this group will receive pharmacogenomic testing guided prescription of pain medication for postoperative dental pain secondary to extraction of impacted mandibular third molar(s)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Selection Criteria:~* Patients with histologically confirmed metastatic colorectal cancer~* No prior chemotherapy for the treatment of metastatic colorectal cancer~* At least one measurable lesion by CT or MRI of ≥ 20 mm (if conventional CT scan) or ≥ 10 mm (if spiral CT scan)~* ECOG Performance Status (ECOG-PS) status ≤ 2~* At least 18 years of age~* Life expectancy \> 6 months~* Must be able and willing to give written informed consent~* Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use acceptable contraceptive methods (abstinence, intrauterine device \[IUD\], oral contraceptive or double barrier device), and must have a negative serum or urine pregnancy test within 1 week prior to beginning treatment on this trial. Nursing patients are excluded. Sexually active men must also use acceptable contraceptive methods (abstinence, condom).~* ANC count greater than or equal to 1,500/ mm³~* Platelets greater than or equal to 100,000/ mm³~* Serum creatinine less than or equal to 2x upper limit of normal (normal range (male): 97-137 mL/min; (female): 88-128 mL/min)~* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 3x the upper limit of normal (≤ 5.0 x ULN is acceptable if liver has tumor involvement) (ALT normal range: \< 41 iu/L (male), \< 31 iu/L (female); AST normal range: \< 37 iu/L (male), \< 31 iu/L (female)).~* Prothrombin Time (PT), activated partial thromboplastin time (aPTT) and INR ≤ 1.5 x ULN (INR normal range: 0.8-1.2) or in the therapeutic range if on anticoagulation.~* Hemoglobin greater than or equal to 9 gm/dl (may be corrected by transfusion prior to 5-FU treatment with investigator approval).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OnDose® (Type: EXPERIMENTAL): Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients' 5-FU dose will be optimized by measuring the Area Under the Curve (AUC) of 5-FU by the commercially available OnDose® assay and their dose for subsequent cycles adjusted following a pre-established dose adjustment algorithm.
- Body Surface Area (BSA) (Type: ACTIVE_COMPARATOR): Patients will receive FOLFOX6 with or without bevacizumab (Avastin). Patients will receive 5-FU based on traditional BSA calculation and their dose adjusted based on standard clinical practice. OnDose® AUC measurements will be performed for this arm but will not be used for dose adjustment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Opioid Consumption After Hospital Discharge in Orthopedic Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age and older, undergoing orthopedic procedures (hip or knee arthroplasty)~* Capable and willing to consent~* Participants literate in English language~Exclusion Criteria:~* History of drug and /or alcohol abuse/ dependency~* Ketamine use during hospitalization~* Illiteracy~* Presence of a clinically diagnosed major psychiatric condition such as bipolar disorder, uncontrolled major depression, schizophrenia~* Any condition that the principle investigator may disqualify the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: None): Adult patients scheduled to undergo a total knee arthroplasty or total hip arthroplasty, who give written informed consent to participate in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ESWT for UE Pain in Patients With Cervical Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Spinal cord damage confirmed in the spinal cord image~2. 1 month after spinal cord injury~3. Spasticity of upper extremities~4. Pain in areas below spinal cord injury more than 4 points on the numerical scale (NRS)~5. Cognitive functions that can clearly point out NRS with more than 15 points in the mini mental state examination (MMSE)~6. Age: 20 and older~7. Person who has agreed in writing to decide his or her participation and comply with the precautions~Exclusion Criteria:~1. Pain due to trauma~2. Injection treatments two weeks before participating in the study~3. Severe coagulopathy (excluding antiplatelet use)~4. Impaired cognition

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: EXPERIMENTAL): 3,000 pulses per time, low energy under 0.3 mJ/mm\^2, tolerable range
- Control group (Type: SHAM_COMPARATOR): Sham therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ATS 3f(r) Aortic Bioprosthesis Model 1000, 19mm

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* This patient requires isolated aortic valve replacement with or without concomitant procedures such as coronary artery bypass or another valve reconstruction. (The three remaining valves must be of native tissue).~* This patient is sufficiently ill to warrant replacement of his/her diseased natural or prosthetic valve, based on standard cardiovascular diagnostic workups.~* This patient is in satisfactory condition, based on the physical exam and investigator's experience, to be an average or better operative risk, (i.e., likely to survive one year postoperatively).~* This patient is geographically stable and willing to return to the implant center for follow-up visits.~* This patient has been adequately informed and consents to his/her participation in the clinical study, and of what will be required of him/her, in order to comply with the protocol.~Exclusion Criteria:~* This patient is twenty (20) or less than twenty years of age.~* This patient has a non-cardiac major or progressive disease, which in the investigator's experience produces an unacceptable increased risk to the patient, or results in a life expectancy of less than 12 months.~* This patient is an intravenous drug and/or alcohol abuser.~* This female patient is pregnant (urine HCG test result positive), or lactating.~* This patient presents with active endocarditis.~* This patient presents with congenital bicuspid aortic anatomy.~* This patient has a previously implanted prosthetic valve that is not being replaced by a study valve.~* This patient requires mitral, tricuspid or pulmonic valve replacement.~* This patient is participating in concomitant research studies of investigational products.~* This patient will not agree to return to the implant center for the required number of follow-up visits or is geographically unavailable for follow-up.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 19mm arotic valve implant (Type: EXPERIMENTAL): Single arm study for patients who require a smaller valve size of the ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues